Huang Y - Search Results

1

Determination of imatinib mesylate and related compounds by field amplified sample stacking with large volume sample injection capillary electrophoresis.

Li J, Huang Y, Huang L, Ye L, Zhou Z, Xiang G, Xu L. Li J, et al. Among authors: huang l, huang y. J Pharm Biomed Anal. 2012 Nov;70:26-31. doi: 10.1016/j.jpba.2012.05.010. Epub 2012 May 14. J Pharm Biomed Anal. 2012. PMID: 22677653

2

Nonaqueous capillary electrophoresis of imatinib mesylate and related substances.

Ye L, Huang Y, Li J, Xiang G, Xu L. Ye L, et al. Among authors: huang y. J Sep Sci. 2012 Aug;35(16):2108-13. doi: 10.1002/jssc.201200114. Epub 2012 Jul 2. J Sep Sci. 2012. PMID: 22753368

3

Novel liposomal gefitinib (L-GEF) formulations.

Zhou X, Yung B, Huang Y, Li H, Hu X, Xiang G, Lee RJ. Zhou X, et al. Among authors: huang y. Anticancer Res. 2012 Jul;32(7):2919-23. Anticancer Res. 2012. PMID: 22753756

4

A novel hydrolysis-resistant lipophilic folate derivative enables stable delivery of targeted liposomes in vivo.

Huang Y, Yang T, Zhang W, Lu Y, Ye P, Yang G, Li B, Qi S, Liu Y, He X, Lee RJ, Xu C, Xiang G. Huang Y, et al. Int J Nanomedicine. 2014 Sep 29;9:4581-95. doi: 10.2147/IJN.S69115. eCollection 2014. Int J Nanomedicine. 2014. PMID: 25302024 Free PMC article.

5

Targeted delivery of chemically modified anti-miR-221 to hepatocellular carcinoma with negatively charged liposomes.

Zhang W, Peng F, Zhou T, Huang Y, Zhang L, Ye P, Lu M, Yang G, Gai Y, Yang T, Ma X, Xiang G. Zhang W, et al. Among authors: huang y. Int J Nanomedicine. 2015 Jul 29;10:4825-36. doi: 10.2147/IJN.S79598. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26251599 Free PMC article.

6

Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.

Cao P, Wu S, Guo W, Zhang Q, Gong W, Li Q, Zhang R, Dong X, Xu S, Liu Y, Shi S, Huang Y, Zhang Y. Cao P, et al. Among authors: huang y. Metabolomics. 2021 Nov 3;17(11):98. doi: 10.1007/s11306-021-01849-5. Metabolomics. 2021. PMID: 34729658

7

A novel immune-related ceRNA network that predicts prognosis and immunotherapy response in lung adenocarcinoma.

Gong WJ, Zhou T, Wu SL, Huang YF, Xiang LP, Xu JQ, Han Y, Lv YN, Zeng F, Zhang Y. Gong WJ, et al. Among authors: huang yf. Ann Transl Med. 2021 Sep;9(18):1484. doi: 10.21037/atm-21-4151. Ann Transl Med. 2021. PMID: 34734036 Free PMC article.

8

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients.

Cao P, Guo W, Wang J, Wu S, Huang Y, Wang Y, Liu Y, Zhang Y. Cao P, et al. Among authors: huang y. Front Pharmacol. 2022 Aug 25;13:954242. doi: 10.3389/fphar.2022.954242. eCollection 2022. Front Pharmacol. 2022. PMID: 36105185 Free PMC article.

9

A novel model to predict the risk of hematological toxicity in lung adenocarcinoma patients with pemetrexed plus platinum chemotherapy based on real-world data.

Gong WJ, Cao P, Huang YF, Liu YN, Yang Y, Zhang R, Li Q, Wu SL, Zhang Y. Gong WJ, et al. Among authors: huang yf. Curr Probl Cancer. 2024 Feb;48:101058. doi: 10.1016/j.currproblcancer.2023.101058. Epub 2023 Dec 15. Curr Probl Cancer. 2024. PMID: 38101085

10

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling.

Gong WJ, Cao P, Zhang QL, Han XY, Wang SW, Huang YF, Wu SL, Li Q, Zhang R, Xu SB, Liu YN, Shi SJ, Zhang Y. Gong WJ, et al. Among authors: huang yf. Transl Oncol. 2022 May;19:101393. doi: 10.1016/j.tranon.2022.101393. Epub 2022 Mar 12. Transl Oncol. 2022. PMID: 35290920 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

82,437 results

Search Page

Filters